European Society for Medical Oncology Congress

COPENHAGEN, Denmark — Omid Hamid, MD, chief of translational research and immunotherapy and director of melanoma therapeutics at The Angeles Clinic and Research Institute, as well as a HemOnc Today Editorial Board member, discusses four trials that evaluated the combination of immuno-oncology agents for the treatment of various solid tumors at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — Corey J. Langer, MD, director of the thoracic oncology program at Abramson Cancer Center of University of Pennsylvania, discusses positive results from cohort G of the KEYNOTE-021 study presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — Corey J. Langer, MD, director of thoracic oncology at University of Pennsylvania Abramson Cancer Center and professor of medicine at the Hospital of the University of Pennsylvania, discusses the changes in the therapeutic landscape of non–small cell lung cancer at the European Society for Medical Oncology Congress.The KEYNOTE-024 trial — designed to evaluate pembrolizumab (Keytruda, Merck) vs. investigator’s choice of platinum-based chemotherapy in untreated patients with advanced NSCLC whose tumors had high PD-L1 expression — demonstrated significantly extended PFS and OS in the pembrolizumab treatment group.

COPENHAGEN, Denmark — Results from the CABOSUN trial may be a “game changer” in the first-line treatment of metastatic renal cell carcinoma, Sumanta K. Pal, MD, a HemOnc Today Editorial Board member and medical oncologist at City of Hope Comprehensive Cancer Center, said at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — A novel BCRA1/2 testing and counseling model expedited time to receive germline testing results and increased patient and staff satisfaction, according to interim results of the prospective, observational ENGAGE study presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark —The addition of irinotecan to FOLFOX chemotherapy and bevacizumab improved response rates and prolonged PFS for the first-line treatment of advanced colorectal cancer, according to results of the randomized phase 2 CHARTA trial presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — Patients who experienced worsening financial burden after cancer diagnosis experienced poorer quality of life and an increased risk for mortality, according to a pooled analysis of 16 trials presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — The addition of selumetinib to second-line docetaxel did not improve outcomes among patients with KRAS–mutant non–small cell lung cancer, according to phase 3 study results presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — The addition of custirsen to cabazitaxel and prednisone did not significantly extended OS in previously treated patients with metastatic, castration-resistant prostate cancer, according to results of the randomized controlled phase 3 AFFINITY trial presented at the European Society for Medical Oncology Congress.

COPENHAGEN, Denmark — Nivolumab did not significantly extend PFS compared with investigator’s choice of platinum-doublet chemotherapy in patients with stage IV or recurrent PD-L1–positive non–small cell lung cancer, according to results of the phase 3 CheckMate 026 trial presented at the European Society for Medical Oncology Congress.